Connection

Robert Harrington to Liver

This is a "connection" page, showing publications Robert Harrington has written about Liver.
Connection Strength

0.091
  1. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Am Heart J. 2016 Oct; 180:22-8.
    View in: PubMed
    Score: 0.091
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.